Nabiximols

• Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review (30 Sep 2024)
  
• An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? (27 Sep 2024)
  
• Cannabinoids in the Older Person: A Literature Review (26 Sep 2024)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review (24 Sep 2024)
  
• Regulation and marketing of cannabidiol-containing products in European countries. Pharmacists’ knowledge in Bulgaria (16 Sep 2024)
  
• Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? (16 Sep 2024)
  
• A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults (16 Sep 2024)
  
• Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England (02 Sep 2024)
  
• Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study (25 Aug 2024)
  
• Safety Considerations in Cannabinoid-Based Medicine (20 Aug 2024)
  
• Cannabinoid Delivery Systems for Pain and Inflammation Treatment (19 Aug 2024)
  
• Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain (13 May 2024)
  
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy (13 May 2024)
  
• A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery (07 Aug 2022)
  
• Medicinal Cannabis and Central Nervous System Disorders (31 Jul 2022)
  
• Differentiating Cannabis Products: Drugs, Food, and Supplements (31 Jul 2022)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review - Journal of Cannabis Research (26 Jul 2022)